| Name | No. | For Patients with | Purpose |
|---|---|---|---|
| INDEPENDENCE ACE-536-MF-002 | 20-34 | Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions |
This Study is to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Placebo in Subjects with Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions. |
DSSG Group: Lymphoma & blood cancers
HOVON 156
| Name | No. | For Patients with | Purpose |
|---|---|---|---|
| HOVON 156 | 19-16 | Newly diagnosed diagnosed acute myeloid leukemia or myelodysplastic syndrome with excess blasts-2 with FLT3 mutations eligible for intensive chemotherapy |
This trial will compare Gilteritinib and midostaurin in combination with induction and consolidation therapy followed by one year maintenance in patients with newly diagnosed Acute Myeloid Leukemia (AML) or Myelodysplastic syndromes with excess blasts-2 (MDS-EB2) with FLT3 mutations eligible for intensive chemotherapy |
HOVON 150
| Name | No. | For Patients with | Purpose |
|---|---|---|---|
| HOVON 150 | 19-18 | Newly diagnosed acute myeloid leukemia or myelodysplastic syndrome with excess blasts-2 with an IDH1 or IDH2 mutation, eligible for intensive chemotherapy |
This trial will compare ivosidenib and enasidenib in combination with induction therapy and consolidation therapy followed by maintenance therapy in patients with newly diagnosed acute myeloid leukemia or myelodysplastic syndrome with excess blasts-2, with an IDH1 or IDH2 mutation, eligible for intensive chemotherapy |
BCNI GMI-1271-301
| Name | No. | For Patients with | Purpose |
|---|---|---|---|
| BCNI GMI-1271-301 | 21-08 | Relapsed/Refractory Acute Myeloid Leukemia (AML) |
This Study is to Determine the Effficacy of Uproleselan (GMI-1271) in Combination With Chemotherapy to Treat Relapsed/Refractory Acute Myeloid Leukaemia |
CLL17
| Name | No. | For Patients with | Purpose |
|---|---|---|---|
| CLL17 | 20-22 | Previously untreated Chronic Lymphocytic Leukaemia (CLL) |
This trial will compare the efficacy of continuous ibrutinib monotherapy with fixed-duration venetoclax plus obinutuzumab and fixed-duration ibrutinib plus venetoclax in patients with previously untreated CLL |
FEDR-MF-002/FREEDOM-2
| Name | No. | For Patients with | Purpose |
|---|---|---|---|
| FEDR-MF-002/FREEDOM-2 | CTRIAL-IE 19-40 | Primary Myelofibrosis, Post-PV or Post-ET Myelofibrosis |
This study will assess the efficacy and safety of fedratinib compared to best available therapy. |
Paradigme (LYMRIT-37-01)
| Name | No. | For Patients with | Purpose |
|---|---|---|---|
| Paradigme (LYMRIT-37-01) | 18-15 | Follicular Lymphoma that did not respond to treatment or recurred after chemotherapy or immunotherapy treatment. |
To investigate the efficacy and safety of a new drug called Betalutin®. One dose of Betalutin® is given to patients. Betalutin® is an antibody which targets a protein on lymphoma cancer cells together with radioactivity to kill the cancer cells. Two doses of Betalutin® are used in this clinical trial and all patients receive Betalutin®. Patients will be requested to return to clinic for up to 5 years to have their cancer assessed and to collect any side effects. |